Latest & greatest articles for nystatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nystatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nystatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nystatin

1. Denture stomatitis: some evidence for nystatin and disinfecting agents

Denture stomatitis: some evidence for nystatin and disinfecting agents Denture stomatitis: some evidence for nystatin and disinfecting agents - National Elf Service Search National Elf Service Search National Elf Service » » » » Denture stomatitis: some evidence for nystatin and disinfecting agents May 10 2017 Posted by Denture stomatitis (DS) is a common oral mucosal lesion of older people. It is characterised by chronic erythema and oedema of some or all the mucosa under removable dentures (...) considered to be at low risk of bias, 3 were unclear and the remainder at high risk of bias. 3 RCTs compared nystatin with placebo demonstrating a signification reduction of clinical signs of stomatitis, RR= 0.51 (95%CI; 0.36–0.72). 4 RCTs compared nystatin with placebo and found a significant effect on mycological assessment, RR= 0.61 (95%CI; 0.46-0.80). 5 RCTs of disinfectant agents showed a significant effect on clinical assessment compared to an inactive agent, RR= 0.52 (95%CI; = 0.30-0.92

2017 The Dental Elf

2. Nystatin

Nystatin Top results for nystatin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for nystatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

3. Oral Thrush - Guidelines for Prescribing Oral Nystatin

Oral Thrush - Guidelines for Prescribing Oral Nystatin Oral Thrush - Guidelines for Prescribing Oral Nystatin - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Oral Thrush - Guidelines for Prescribing Oral Nystatin Oral thrush is a fungal infection of the oral mucosa caused by Candida species. It is the most common human fungal infection. Oral thrush may refer to candidiasis in the mouths of babies, or if occurring in the mouth (...) : Apply to affected area once or twice daily. Solutions diluted to 0.25% to 0.5% may be less irritating. Apply with cotton-tipped applicator directly to affected area inside mouth. Do not allow to be swallowed. Not usually first line treatment. Requires longer duration of treatment. Messy - stains skin and clothing. Associated with ulceration of mucosa. 3. Prescription Drug Option: Nystatin Suspension 100,000 units/ml Treatment option for mild disease (level 2 [mid-level] evidence) Dosage Children

2017 medSask

4. Recurrence of vulvovaginal candidosis during pregnancy. Comparison of miconazole vs nystatin treatment. (Abstract)

Recurrence of vulvovaginal candidosis during pregnancy. Comparison of miconazole vs nystatin treatment. The efficacy of miconazole and nystatin in the treatment of vulvovaginal candidosis was compared in a multicenter trial involving 94 pregnant patients. All patients had subjective complaints and were mycologically positive. Miconazole 2% vaginal cream was applied once daily for at least 10 days by 45 patients, whereas the 49 others received nystatin tablets for intravaginal application during (...) 7 to 9 days. At the first examination following treatment, the cure rate with miconazole was 83% and with nystatin 68%. Follow-up examinations revealed a significantly lower recurrence rate in the miconazole-treated group. No important adverse experiences were noted.

1976 Obstetrics and Gynecology

5. Nifuratel-Nystatin combination for the treatment of mixed infections of bacterial vaginosis, vulvovaginal candidiasis, and trichomonal vaginitis [Cochrane protocol]

Nifuratel-Nystatin combination for the treatment of mixed infections of bacterial vaginosis, vulvovaginal candidiasis, and trichomonal vaginitis [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2018 PROSPERO

6. Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin

Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

7. Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis

Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01427738 Recruitment Status : Completed First Posted : September 2, 2011 Results First Posted : February 16, 2015 Last Update Posted : February 16

2010 Clinical Trials

8. Nystatin-like Pseudonocardia polyene B1, a novel disaccharide-containing antifungal heptaene antibiotic (Full text)

Nystatin-like Pseudonocardia polyene B1, a novel disaccharide-containing antifungal heptaene antibiotic Polyene macrolides such as nystatin A1 and amphotericin B belong to a large family of very valuable antifungal polyketide compounds typically produced by soil actinomycetes. Recently, nystatin-like Pseudonocardia polyene (NPP) A1 has been identified as a unique disaccharide-containing tetraene antifungal macrolide produced by Pseudonocardia autotrophica. Despite its significantly increased (...) water solubility and decreased hemolytic activity, its antifungal activity remains limited compared with that of nystatin A1. In this study, we developed NPP B1, a novel NPP A1 derivative harboring a heptaene core structure, by introducing two amino acid substitutions in the putative NADPH-binding motif of the enoyl reductase domain in module 5 of the NPP A1 polyketide synthase NppC. The low level NPP B1 production yield was successfully improved by eliminating the native plasmid encoding

2018 Scientific reports PubMed abstract

9. Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. (Full text)

Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. To systematically review and assess the efficacy, different treatment protocols (formulation, dosage, and duration), and safety of nystatin for treating oral candidiasis.Four electronic databases were searched for trials published in English till July 1, 2015. Randomized controlled trials comparing nystatin with other antifungal therapies or a placebo were included. Clinical and/or mycological (...) cure was the outcome evaluation. A meta-analysis or descriptive study on the efficacy, treatment protocols, and safety of nystatin was conducted.The meta-analysis showed that nystatin pastille was significantly superior to placebo in treating denture stomatitis. Nystatin suspension was not superior to fluconazole in treating oral candidiasis in infants, children, or HIV/AIDS patients. The descriptive investigations showed that administration of nystatin suspension and pastilles in combination for 2

2016 Drug design, development and therapy PubMed abstract

10. Nystatin prophylaxis and treatment in severely immunodepressed patients. (Full text)

Nystatin prophylaxis and treatment in severely immunodepressed patients. Nystatin is sometimes used prophylactically in patients with severe immunodeficiency or in the treatment of fungal infection in such patients, although its effect seems to be equivocal.To study whether nystatin decreases morbidity and mortality when given prophylactically or therapeutically to patients with severe immunodeficiency.We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified (...) articles.Randomised clinical trials comparing nystatin with placebo, an untreated control group, fluconazole or amphotericin B.Data on mortality, invasive fungal infection and colonisation were independently extracted by both authors. A random-effects model was used unless the P value was greater than 0.10 for the test of heterogeneity.We included 14 trials (1569 patients). The drugs were given prophylactically in 12 trials and as treatment in two. Eleven trials were in acute leukaemia, solid cancer, or bone

2014 Cochrane PubMed abstract

11. Microwave denture disinfection versus nystatin in treating patients with well-controlled type 2 diabetes and denture stomatitis: a randomized clinical trial. (Abstract)

Microwave denture disinfection versus nystatin in treating patients with well-controlled type 2 diabetes and denture stomatitis: a randomized clinical trial. The aim of this randomized clinical trial was to compare the effectiveness of microwave denture disinfection and nystatin in the treatment of well-controlled type 2 diabetic patients with denture stomatitis in terms of microbiologic and clinical outcomes.Diabetic patients wearing maxillary complete dentures with denture stomatitis (n = 40 (...) ) were divided into two groups: NYS (patients treated with topical nystatin 4 times/day for 14 days) and MW (patients who had their dentures microwaved [650 W for 3 minutes] 3 times/week for 14 days). Mycologic samples were taken from the palates and dentures of the patients for quantification and identification of Candida, and standardized photographs of the palates were taken for clinical analysis. Evaluations were repeated at baseline, the end of treatment (day 14), and throughout follow-up (days

2012 The International journal of prosthodontics Controlled trial quality: uncertain

12. A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome. (Abstract)

A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome. Candida albicans infection has been proposed to cause a chronic hypersensitivity syndrome characterized by fatigue, premenstrual tension, gastrointestinal symptoms, and depression. Long-term antifungal therapy has been advocated as treatment for the syndrome, which is most often diagnosed in women with persistent or recurrent candida vaginitis.To determine the efficacy of nystatin therapy (...) for presumed candidiasis hypersensitivity syndrome, we conducted a 32-week randomized, double-blind, cross-over study using four different combinations of nystatin or placebo given orally or vaginally in 42 premenopausal women who met present criteria for the syndrome and had a history of candida vaginitis. The outcomes studied were the changes from base line in scores for vaginal, systemic, and overall symptoms and in the results of standardized psychological tests.The three active-treatment regimens

1990 NEJM Controlled trial quality: predicted high

13. A comparative clinical evaluation of econazole nitrate, miconazole, and nystatin in the treatment of vaginal candidiasis. (Abstract)

A comparative clinical evaluation of econazole nitrate, miconazole, and nystatin in the treatment of vaginal candidiasis. A controlled triple open clinical study on three vaginal tablets--Econazole nitrate, Miconazole and Nystatin, was carried out. Seventy-five patients, aged between 18 and 45 years, presenting with mycologically proven cases of vaginal candidiasis, met certain set criteria and were admitted into the study. Twenty-five patients were randomly assigned to each of the three (...) treatment groups. Results of the study showed that at the 4th week after treatment, Econazole was comparable in antifungal action to Miconazole (x2 = 0.2128; p > 0.05) but significantly more antifungal than Nystatin (x2 = 8.8540; P < 0.05), although the overall clinicomycological assessment of the drugs showed no significant difference in their ratings (F = 21.34; P > 0.05).

2000 West African journal of medicine Controlled trial quality: uncertain

14. Oral Nystatin Versus Intravenous Fluconazole as Neonatal Antifungal Prophylaxis: Non-inferiority Trial. (Full text)

Oral Nystatin Versus Intravenous Fluconazole as Neonatal Antifungal Prophylaxis: Non-inferiority Trial. Fluconazole has shown to be effective in reducing both colonization and invasive Candida infection (ICI) in ELBW neonates; we conducted a randomized trial to compare oral nystatin with intravenous fluconazole for prophylaxis against invasive Candidiasis in high risk neonates.By using SPSS, preterm less than 30 weeks gestation and/or birth weight 1200 grams or less assigned to receive either (...) intravenous Fluconazole (6 mg/kg q72 hr for 1(st) week then q48 h for 6 wks) or oral Nystatin (100,000 unit q8 hr for 6 wks). The medications commenced at one week of age after obtaining the base line investigations and check for Candida colonization by urine culture and rectal swab; subsequently all lab work and the clinical data were monitered regularly. Risk factors were assessed. The data collected prospectively looking for primary end point the invasive Candida infection (ICI) and 2 ndry outcomes

2013 Journal of clinical neonatology Controlled trial quality: uncertain PubMed abstract

15. Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections

Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02186145

2014 Clinical Trials

16. Topical gentian violet compared to nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1 Infected participants. (Full text)

Topical gentian violet compared to nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1 Infected participants. Compare the safety and efficacy of topical gentian violet with that of nystatin oral suspension (NYS) for the treatment of oropharyngeal candidiasis in HIV-1-infected adults in resource-limited settings.Multicenter, open-label, evaluator-blinded, randomized clinical trial at eight international sites, within the AIDS Clinical Trials Group.Adult HIV-infected

2016 AIDS Controlled trial quality: predicted high PubMed abstract

17. Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants

Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03390374 Recruitment Status : Completed First Posted : January 4, 2018 Last Update Posted

2017 Clinical Trials

18. The Ion Permeability Induced in Thin Lipid Membranes by the Polyene Antibiotics Nystatin and Amphotericin B (Full text)

The Ion Permeability Induced in Thin Lipid Membranes by the Polyene Antibiotics Nystatin and Amphotericin B Characteristics of nystatin and amphotericin B action on thin (<100 A) lipid membranes are: (a) micromolar amounts increase membrane conductance from 10(-8) to over 10(-2) Omega(-1) cm(-2); (b) such membranes are (non-ideally) anion selective and discriminate among anions on the basis of size; (c) membrane sterol is required for action; (d) antibiotic presence on both sides of membrane (...) since four polyene antibiotics, each containing two-NH(3) (+) groups, induce ideal cation selectivity. Possibly the many hydroxyl groups in nystatin and amphotericin B are responsible for anion selectivity. The effects of polyene antibiotics on thin lipid membranes are consistent with their action on biological membranes.

1970 The Journal of general physiology PubMed abstract

19. [Comparative study of combined local treatment (sulfadimidine, metronidazole and nystatin) and the standard monotherapy in uncomplicated bacterial vaginosis]. (Abstract)

[Comparative study of combined local treatment (sulfadimidine, metronidazole and nystatin) and the standard monotherapy in uncomplicated bacterial vaginosis]. Comparative, in vivo, human, prospective, single blind, clinical and microbiological diagnoses based and randomised study of the treatment of uncomplicated bacterial vaginosis with two forms of combined (metronidazole + nystatin + sulfadimidin) vaginal suppositories (laminated and mixed containing the same ingredients) and the standard

2002 Orvosi hetilap

20. Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. (Abstract)

Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. This study aims to compare the efficacy of orally administered Saccharomyces boulardii versus nystatin in prevention of fungal colonization and invasive fungal infections in very low birth weight infants.A prospective, randomized comparative study was conducted in preterm infants with a gestational age of ≤ 32 weeks and birth weight of ≤ 1,500 g (...) . They were randomized into two groups, to receive S. boulardii or nystatin. Skin and stool cultures were performed for colonization and blood cultures for invasive infections, weekly.A total of 181 infants were enrolled (S. boulardii group, n = 91; nystatin group, n = 90). Fungal colonization of the skin (15.4 vs 18.9 %, p = 0.532) and the stool (32.2 vs 27 %, p = 0.441) were not different between the probiotic and nystatin groups. Two patients had Candida-positive blood culture in the nystatin group

2013 European journal of pediatrics Controlled trial quality: uncertain